Demant maintains guidance, sees lower-end outcome as "less likely"

The hearing health company continues to expect organic growth of 3–6%.

No actionable change — this is a corporate financial update with no clinical or practice implications.

Demant's confidence in its growth trajectory signals continued investment capacity in hearing technology R&D and market expansion.

1. 01Demant maintains 2026 organic growth guidance of 3–6%.
2. 02Management characterizes a lower-end outcome as 'less likely'.
3. 03Update reported by trade publication MedWatch, not a company investor release.
4. 04No product, clinical, or regulatory news included in the update.